



## Curriculum Vitae

Personal information **Yanna-Marina Chevalme**

### Work experience

---

1. Employer: ANSM
  - Start date: 2001
  - End date:
  - Position: Diagnostic Products (radiopharmaceuticals and contrast media) Assessor
  - Activities: \_ marketing authorisation evaluator for radiopharmaceutical (pharmaceutical, preclinical and clinical) \_ scientific advice on development and clinical trials for diagnostic agents and therapeutic radiopharmaceuticals. \_ Member of the working party on radiopharmaceuticals at EMA (European Medicines Agency). • Rapporteur for the core PIL, core FDG SmPC and core FNA SmPC • Delegate of Afssaps and Ansm at OCDE concerning the global market of technetium\_99m
  - Country: France
2. Employer: AFSSAPS
  - Start date: 1992
  - End date: 2001
  - Position: Radiopharmaceuticals Assessor
  - Activities: \_ marketing authorisation evaluator for radiopharmaceutical (pharmaceutical, preclinical and clinical) \_ advice on PSUR. \_ Member of the working party on radiopharmaceuticals at Bruxelles then EMEA (European Medicines Agency).
  - Country: France
3. Employer: AFSSAPS
  - Start date: 1987
  - End date: 1992
  - Position: Radiopharmaceuticals Assessor
  - Activities: \_ marketing authorisation dossier on pharmaceutical
  - Country: France

### Education and training

---

1. Subject: University of Pharmacy (Paris XI)
  - Start date: 1987
  - End date: 1987
  - Qualification: PharmD
  - Organisation:
  - Country: France
2. Subject: University of Law (Sceaux)
  - Start date: 1986
  - End date: 1986
  - Qualification: Master in Health Law
  - Organisation:
  - Country: France

### Additional information

---

#### Publications

Majors Representative references for the past ten years 1. Chevalme Y. How the French Medecine Authority addressed the technetium crisis information. J Nucl Med. 2009; 50 (Supplement 2): 1369 2. Talbot JN, Kerrou K, Montravers F, Nataf V, Chevalme Y. FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines. Eur J Nucl Med Mol Imaging 2007; 34 (7): 1131\_2 3. Talbot JN, Chevalme Y. Current evaluation of the clinical utility of Fluoromethylcholine\_(18F) PET/CT in prostate cancer. Braz. arch. biol. technol. [online]. 2008; 51 (n.spe) : 71\_75 . 4. Chevalme Y, Montravers F; Vuillez JP, Zanca M, Fallais C, et al..FDOPA\_(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Braz. arch. biol. technol. [online]. 2007 ; 50 (n.spe) : 77\_90 . 5. Chevalme Y. Registration of pharmaceutical and radiopharmaceutical drugs: French and European regulations. Med Nucl 2005; 29 (4): 165\_16

#### Projects

#### Memberships

#### Other Relevant Information

\_ Quality insurance and normes ISO 9000 \_ Since 1996 regular attendance of French congress of nuclear medecine and of radiology. \_ Since 2000 regular attendance to the European congress of Nuclear Medicine (EANM) and Radiological Society of North America (RSNA)